Aditum Bio
Venture capitalOakland · Series A–Series B
Investment thesis
Legacy drug development models are inefficient and fail to address important unmet medical needs. Aditum Bio pursues an alternative, patient-centric approach by identifying promising clinic-ready therapeutic candidates that traditional drug developers have deprioritized due to strategic constraints or prohibitive trial costs. Using in-house R&D expertise, experienced leadership teams, and proprietary technology platforms, the firm accelerates portfolio companies through development phases while maintaining lean operations and reducing overall development timelines and costs compared to conventional models.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 5 of 6 portfolio companiesBiotech ×5Medical Devices ×5Digital Health ×3Healthtech ×2
HQs:United States×4
Investments · 6 tracked
founders shown can be your intro pathCoastline Bio is a biopharmaceutical company developing novel medicines for immunological skin diseases, with an initial focus on atopic dermatitis. The company is developing a first-in-class monoclonal antibody targeting disease pathways in skin conditions.
BiotechHealthtechMedical DevicesOakland, US
Celexor Bio develops monoclonal antibody therapeutics targeting plasmacytoid dendritic cells to treat severe autoimmune and inflammatory disorders by interrupting the inflammatory cascade at its source. The company's lead candidate, CLXR-901, is designed to deplete pathological pDCs and modify disease progression in underserved patient populations.
BiotechDigital HealthMedical DevicesOakland, US
Kalexo Bio develops dual-targeting siRNA therapeutics for cardiovascular disease, with a focus on lipid management and atherosclerotic disease prevention. The company's lead program targets genetic drivers of cardiovascular risk to deliver durable risk reduction in patients.
BiotechDigital HealthMedical Devices
Oblenio Bio develops LBL-051, a tri-specific T-cell engager therapy targeting BCMA, CD19, and CD3 for treating refractory autoimmune diseases through B-cell and plasma cell depletion. The company aims to achieve long-term drug-free remission in autoimmune disease patients.
BiotechHealthtechMedical DevicesLexington, US
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.
BiotechDigital HealthMedical Devices
Board seats · per SEC filings
what is this? ⓘ$77M raise · filed Nov 2025 · via Joseph Jimenez, Joshua Gertsman
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Aditum Bio invest at?
- Aditum Bio invests at the Series A, Series B stages.
- What sectors does Aditum Bio focus on?
- Aditum Bio focuses on AI & Machine Learning, Biotech.
- Where is Aditum Bio located?
- Aditum Bio is headquartered in Oakland, US.
Images
Similar investors
a16z is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz that invests in seed through growth-stage technology companies across multiple sectors including AI, healthcare, consumer, crypto, enterprise, fintech, and gaming. The firm manages over $100 billion in assets and operates a distinctive platform model with a large team of operators supporting founders throughout their journey.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Bessemer Venture Partners is a venture capital firm with a 50-year history supporting entrepreneurs in building enduring companies globally. The firm draws on deep operational expertise and advisory relationships to support portfolio companies through their growth journey.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.